Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
Cardiomyopathies have unresolved genotype–phenotype relationships and lack disease-specific treatments. Here we provide a framework to identify genotype-specific pathomechanisms and therapeutic targets to accelerate the development of precision medicine. We use human cardiac electromechanical in-sil...
Egile Nagusiak: | Margara, F, Psaras, Y, Wang, ZJ, Schmid, M, Doste, R, Garfinkel, AC, Repetti, GG, Seidman, JG, Seidman, CE, Rodriguez, B, Toepfer, CN, Bueno-Orovio, A |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
Springer Nature
2022
|
Antzeko izenburuak
-
Pharmacological management of hypertrophic cardiomyopathy: From bench to bedside
nork: Palandri, C, et al.
Argitaratua: (2022) -
CalTrack: high throughput automated calcium transient analysis in cardiomyocytes
nork: Psaras, Y, et al.
Argitaratua: (2021) -
Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin
nork: Toepfer, C, et al.
Argitaratua: (2019) -
Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy
nork: Toepfer, CN, et al.
Argitaratua: (2020) -
Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
nork: Coleman, JA, et al.
Argitaratua: (2024)